Randomized phase II trial of three intrapleural therapy regimens for the management of malignant pleural effusion in previously untreated non-small cell lung cancer: JCOG 9515

Lung Cancer

Volumn 58, Issue 3, 2007, Pages 362-368

  Yoshida, Kimihide ^a   Sugiura, Takahiko ^a   Takifuji, Nobuhide ^b   Kawahara, Masaaki ^c   Matsui, Kaoru ^d   Kudoh, Shinzoh ^e   Takada, Minoru ^f   Fukuoka, Masahiro ^g   Ariyoshi, Yutaka ^h   Fukuda, Haruhiko ⁱ   Saijo, Nagahiro ^j  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA CITY GENERAL HOSPITAL   (Japan)

^c Natl Kinki Chuo Hosp Chest Dis   (Japan)

^d OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^e Osaka Prefecture University   (Japan)

^f Department of Cardiology   (Japan)

^g KINKI UNIVERSITY   (Japan)

^h AICHI PREFECTURAL UNIVERSITY   (Japan)

ⁱ NATIONAL CANCER CENTER   (Japan)

^j NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

more..

Author keywords

Bleomycin; Cisplatin plus etoposide; Intrapleural therapy; Malignant pleural effusion; Management of malignant pleural effusion; Non small cell lung cancer; OK 432

Indexed keywords

BLEOMYCIN; CISPLATIN; ETOPOSIDE; PICIBANIL;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PYOGENES;

ADULT; AGED; BLEOMYCIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PICIBANIL; PLEURAL EFFUSION, MALIGNANT; SURVIVAL RATE;

EID: 35748931187     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.07.009     Document Type: Article

References (43)

1. Figlin R., Mendoza E., Piantadosi S., and Rusch V. Intrapleural chemotherapy without pleurodesis for malignant pleural effusions. LCSG Trial 861. Chest 106 (1994) 363S-366S
2. Rusch V.W., Figlin R., Godwin D., and Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol 9 (1991) 313-319
3. Windsor P.G., Como J.A., and Windsor K.S. Sclerotherapy for malignant pleural effusions: alternatives to tetracycline. South Med J 87 (1994) 709-714
4. Walker-Renard P.B., Vaughan L.M., and Sahn S.A. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 120 (1994) 56-64
5. Grossi F., Pennucci M.C., Tixi L., et al. Management of malignant pleural effusions. Drugs 55 (1998) 47-58
6. Ruckdeschel J.C. Management of malignant pleural effusions. Semin Oncol 22 (1995) 58-63
7. Zimmer P.W., Hill M., Casey K., et al. Prospective randomized trial of talc slurry vs bleomycin in pleurodesis for symptomatic malignant pleural effusions. Chest 112 (1997) 430-434
8. Sartori S., Tassinari D., Ceccotti P., et al. Prospective randomized trial of intrapleural bleomycin versus interferon alfa-2b via ultrasound-guided small-bore chest tube in the palliative treatment of malignant pleural effusions. J Clin Oncol 22 (2004) 1228-1233
9. Kimura I., Ohnoshi T., Yasuhara S., et al. Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer 37 (1976) 2201-2203
10. Sakamoto J., Teramukai S., Watanabe Y., et al. Meta-analysis of adjuvant immunochemotherapy using OK-432 in patients with resected non-small-cell lung cancer. J Immunother 24 (2001) 250-256
11. Luh K.T., Yang P.C., Kuo S.H., et al. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer 69 (1992) 674-679
12. Saka H., Shimokata K., Watanabe A., Saito H., Minami H., and Sakai S. Randomized comparison of OK-432 and Bleomycin in intrapleural therapy for malignant effusions. Proc Am Soc Clin Oncol 450a (1994) [Abstr 1555]
13. Tohda Y., Iwanaga T., Takada M., et al. Intrapleural administration of cisplatin and etoposide to treat malignant pleural effusions in patients with non-small cell lung cancer. Chemotherapy 45 (1999) 197-204
14. Tobinai K., Kohno A., Shimada Y., et al. Toxicity grading criteria of the Japan Clinical Oncology Group. The Clinical Trial Review Committee of the Japan Clinical Oncology Group. Jpn J Clin Oncol 23 (1993) 250-257
15. Simon R., Wittes R.E., and Ellenberg S.S. Randomized phase II clinical trials. Cancer Treat Rep 69 (1985) 1375-1381
16. Armitage P., and Berry G. Survival analysis. Statistical Methods in Medical Research (1994), Blackwell Scientific Publications, Oxford, United Kingdom
17. Ostrowski M.J. Intracavitary therapy with bleomycin for the treatment of malignant pleural effusions. J Surg Oncol Suppl 1 (1989) 7-13
18. Ruckdeschel J.C., Moores D., Lee J.Y., et al. Intrapleural therapy for malignant pleural effusions. A randomized comparison of bleomycin and tetracycline. Chest 100 (1991) 1528-1535
19. Paladine W., Cunningham T.J., Sponzo R., et al. Intracavitary bleomycin in the management of malignant effusions. Cancer 38 (1976) 1903-1908
20. Bitran J.D., Brown C., Desser R.K., et al. Intracavitary bleomycin for the control of malignant effusions. J Surg Oncol 16 (1981) 273-277
21. Ostrowski M.J., Priestman T.J., Houston R.F., and Martin W.M. A randomized trial of intracavitary bleomycin and Corynebacterium parvum in the control of malignant pleural effusions. Radiother Oncol 14 (1989) 19-26
22. Hamed H., Fentiman I.S., Chaudary M.A., and Rubens R.D. Comparison of intracavitary bleomycin and talc for control of pleural effusions secondary to carcinoma of the breast. Br J Surg 76 (1989) 1266-1267
23. Hartman D.L., Gaither J.M., Kesler K.A., et al. Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions. J Thorac Cardiovasc Surg 105 (1993) 743-747 [Discussion747-8]
24. Dresler C.M., Olak J., Herndon II J.E., et al. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest 127 (2005) 909-915
25. Rinaldo J.E., Owens G.R., and Rogers R.M. Adult respiratory distress syndrome following intrapleural instillation of talc. J Thorac Cardiovasc Surg 85 (1983) 523-526
26. Bouchama A., Chastre J., Gaudichet A., et al. Acute pneumonitis with bilateral pleural effusion after talc pleurodesis. Chest 86 (1984) 795-797
27. Janssen J.P., Collier G., Astoul P., et al. Safety of pleurodesis with talc poudrage in malignant pleural effusion: a prospective cohort study. Lancet 369 (2007) 1535-1539
28. Shaw P, Agarwal R. Pleurodesis for malignant pleural effusions. Cochrane Database Syst Rev (database online) 2004.
29. Aelony Y. Talc pleurodesis and acute respiratory distress syndrome. Lancet 369 (2007) 1494-1496
30. Yasue M., Murakami M., Nakazato H., et al. A controlled study of maintenance chemoimmunotherapy vs immunotherapy alone immediately following palliative gastrectomy and induction chemoimmunotherapy for advanced gastric cancer. Tokai cooperative study group for adjuvant chemoimmunotherapy of stomach cancer. Cancer Chemother Pharmacol 7 (1981) 5-10
31. Watanabe Y., and Iwa T. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Mod 6 (1987) 169-180
32. Katano M., and Morisaki T. The past, the present and future of the OK-432 therapy for patients with malignant effusions. Anticancer Res 18 (1998) 3917-3925
33. Uchida A., and Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst 71 (1983) 673-680
34. Wei Y., Zhao X., Kariya Y., et al. Induction of autologous tumor killing by heat treatment of fresh human tumor cells: involvement of gamma delta T cells and heat shock protein 70. Cancer Res 56 (1996) 1104-1110
35. Kitsuki H., Katano M., Ikubo A., et al. Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. Clin Immunol Immunopathol 78 (1996) 283-290
36. Markman M. Intracavitary chemotherapy. Curr Probl Cancer 10 (1986) 401-437
37. Aitini E., Cavazzini G., Pasquini E., et al. Treatment of primary or metastatic pleural effusion with intracavitary cytosine arabinoside and cisplatin. A phase II study. Acta Oncol 33 (1994) 191-194
38. Sugiura S., Ando Y., Minami H., et al. Prognostic value of pleural effusion in patients with non-small cell lung cancer. Clin Cancer Res 3 (1997) 47-50
39. Miles D.W., and Knight R.K. Diagnosis and management of malignant pleural effusion. Cancer Treat Rev 19 (1993) 151-168
40. Rusch V.W. The optimal treatment of malignant pleural effusions. A continuing dilemma. Chest 100 (1991) 1483-1484
41. Dryzer S.R., Allen M.L., Strange C., et al. A comparison of rotation and nonrotation in tetracycline pleurodesis. Chest 104 (1993) 1763-1766
42. Mager H.J., Maesen B., Verzijlbergen F., et al. Distribution of talc suspension during treatment of malignant pleural effusion with talc pleurodesis. Lung Cancer 36 (2002) 77-81
43. Pfister D.G., Johnson D.H., Azzoli C.G., et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22 (2004) 330-353